January 12, 2024 09:58 AM EST

Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice's deal in SEA

Jaimy Lee

Deputy Editor

Anna Brown

News Reporter

Ji Xing acquires Biogen’s experimental therapy for acute ischemic stroke: The Shanghai-based biopharma did not disclose the financial terms of the deal. Back in 2018 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice's deal in SEA

Jaimy Lee

Deputy Editor

Anna Brown

News Reporter

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Ji Xing buys Bio­gen’s acute is­chemic stroke drug; Ex­elix­is/BioIn­vent part­ner­ship ends; Clin­Choice's deal in SEA

Deputy Editor

News Reporter

Sign up to read this article for free.

Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice's deal in SEA